
    
      Acute invasive fungal infections caused by aspergillus, rare moulds, yeasts or dimorphic
      fungi are life threatening diseases. Early treatment with highly effective anti-fungals
      reduces mortality. This study investigates the safety and efficacy of isavuconazole in
      participants with aspergillosis and renal impairment, and in participants suffering from
      invasive infections from rare fungi.
    
  